99
Participants
Start Date
December 15, 2015
Primary Completion Date
October 16, 2019
Study Completion Date
October 24, 2019
Lanreotide autogel 120 mg
AVL/NKI Medisch Oncologie, Amsterdam
Erasme Hospital, Brussels
Academic Medical Center, Amsterdam
Cliniques Unversitaires Saint Luc, Brussels
Rigshospitalet, Copenhagen
Antwerp University Hospital, Edegem
Erasmus MC, Rotterdam
Institut Paoli Calmette, Marseille
Charité - CVK, Berlin
IRCCS Azienda Ospedaliera Universitaria, San Martino
Fondacione IRCCS Istituto Nazionale Dei Tumori, Milan
Hospital Universitario Ramón Y Cajal, Madrid
Hospital Universitario 12 De Octubre, Madrid
Hospital Universitario Central de Asturias, Oviedo
Azienda Ospedaliera - Universitaria Careggi, Florence
Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg
Hôpital Edouard Herriot, Lyon
"Università degli Studi Federico II di Napoli", Napoli
Universitätsklinikum Erlangen, Erlangen
Hôpital Beaujon, Clichy
Institut Gustave Roussy, Villejuif
UZ Leuven, Leuven
Aarhus University Hospital, Aarhus
St Vincent's University Hospital, Dublin
Azienda Ospedaliera sant'Andrea, Roma
Samodzielny Publiczny Szpital Kliniczny nr 5, Katowice
Katedra i Klinika Endokrynologii, Poznan
"Centrum Diagnostyczno-Lecznicze GAMMED", Warsaw
Hospital Universitario Vall D'hebron, Barcelona
Queen Elizabeth Medical Center, Birmingham
Royal Free Hospital, London
The Christie Hospital NHS Foundation Trust, Manchester
Lead Sponsor
Ipsen
INDUSTRY